Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on September 9, 2015. The report discloses the entry into an underwriting agreement for a public offering of common stock. Note: The request metadata references "Neurogene Inc.," but the filing text explicitly identifies the registrant as Aquinox Pharmaceuticals, Inc.
Key Financial Metrics
- Offering Size: 5,500,000 shares of common stock.
- Public Offering Price: $15.50 per share.
- Underwriter Purchase Price: $14.57 per share.
- Expected Net Proceeds: Approximately $79.8 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 825,000 shares.
Material Changes
The filing reports a material capital event: the execution of an underwriting agreement with Leerink Partners LLC. This represents a significant increase in the company's equity capital base compared to the prior period, though specific prior period financial statements are not included in this current report.
Guidance, Outlook, and Risks
The filing does not provide specific operational guidance, revenue outlook, or management commentary regarding future performance beyond the capital raise. The document notes that the Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The legality of the issuance is supported by an opinion from Cooley LLP.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $79.8 million figure is an estimate.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 825,000 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or restrictive covenants.
- Check subsequent filings to determine the intended use of the raised capital.